title: Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
abstract: A new study shows that the BRAF inhibitor vemurafenib may induce partial responses and stable disease in patients with papillary thyroid cancer that has become refractory to radioactive iodine. However, the drug led to a variety of serious adverse events in roughly 65% of patients, including the development of some squamous cell carcinomas.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002291:Carcinoma, Papillary; D002294:Carcinoma, Squamous Cell / Q000209:etiology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D007457:Iodine Radioisotopes; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf